BNGO

Bionano Genomics, Inc. (NASDAQ:BNGO) is a medical diagnostics and research company founded in 2003 and headquartered in San Diego, California. The company went public in August 2018 and specializes in genome analysis software solutions, particularly through its flagship <b>Optical Genome Mapping (OGM)</b> technology. Originally focused on aggressive growth and customer acquisition, Bionano has undergone significant strategic restructuring since 2024, pivoting from expansion to profitability by dramatically reducing its workforce from over 400 to under 125 employees and focusing on supporting its existing customer base of routine users.